.
orchid pharma faces liquidation as lenders reject resolution plan
.
in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
.
�we have waited a long time and we cannot possibly wait any longer.�
.